排序方式: 共有84条查询结果,搜索用时 31 毫秒
11.
12.
13.
14.
15.
16.
17.
18.
Jayashree Shanker Ganapathy Perumal Arindam Maitra Veena S. Rao B. K. Natesha Shibu John Sridhar Hebbagodi Vijay V. Kakkar 《Journal of genetics》2009,88(3):291-297
Elevated factor VII (FVII) level is a risk factor for coronary artery disease (CAD). We investigated the role of R353Q polymorphism
in the F7 gene in 139 Indian families with CAD, comprising of 222 affected subjects, 105 unaffected subjects and 126 affected sibling
pairs. Plasma per cent FVIIc activity (FVII.c activity) differed significantly across R353Q genotype (P < 0.0001). Frequency of subjects with RR and QQ genotypes were higher in 4th quartile and 1st quartile of FVII.c activity,
respectively (P < 0.0001). F7 R353Q SNP was able to explain up to 7% of variation in FVII.c activity by regression analysis and an additive genetic component
of variance of 28.04% by heritability analysis. Quantitative trait loci analysis showed suggestive linkage evidence of F7 SNP with per cent FVII.c activity (LOD score −1.82; P = 0.002). Individuals with RR and RQ genotypes carried an OR of 2.071 (95% c.i. = 1.506−2.850) and 2.472 (95% c.i. = 1.679−3.641),
respectively, towards CAD risk. There was significant correlation of FVII.c activity with lipid markers, particularly among
those with RR and RQ genotype after covariate adjustment. In conclusion, the F7 R353Q SNP appears to moderately influence plasma FVII.c activity and risk of CAD in Indians. 相似文献
19.
Girish V. Shah Anbalagan Muralidharan Mitan Gokulgandhi Kamal Soan Shibu Thomas 《The Journal of biological chemistry》2009,284(2):1018-1030
Calcitonin, a neuroendocrine peptide, and its receptor are localized in the
basal epithelium of benign prostate but in the secretory epithelium of
malignant prostates. The abundance of calcitonin and calcitonin receptor mRNA
displays positive correlation with the Gleason grade of primary prostate
cancers. Moreover, calcitonin increases tumorigenicity and invasiveness of
multiple prostate cancer cell lines by cyclic AMP-dependent protein
kinase-mediated actions. These actions include increased secretion of matrix
metalloproteinases and urokinase-type plasminogen activator and an increase in
prostate cancer cell invasion. Activation of calcitonin-calcitonin receptor
autocrine loop in prostate cancer cell lines led to the loss of cell-cell
adhesion, destabilization of tight and adherens junctions, and internalization
of key integral membrane proteins. In addition, the activation of
calcitonin-calcitonin receptor axis induced epithelial-mesenchymal transition
of prostate cancer cells as characterized by cadherin switch and the
expression of the mesenchymal marker, vimentin. The activated calcitonin
receptor phosphorylated glycogen synthase kinase-3, a key regulator of
cytosolic β-catenin degradation within the WNT signaling pathway. This
resulted in the accumulation of intracellular β-catenin, its
translocation in the nucleus, and transactivation of β-catenin-responsive
genes. These results for the first time identify actions of
calcitonin-calcitonin receptor axis on prostate cancer cells that lead to the
destabilization of cell-cell junctions, epithelial-to-mesenchymal transition,
and activation of WNT/β-catenin signaling. The results also suggest that
cyclic AMP-dependent protein kinase plays a key role in calcitonin
receptor-induced destabilization of cell-cell junctions and activation of
WNT-β-catenin signaling.Prostate cancer
(PC)2 is the most
commonly diagnosed cancer and the second leading cause of cancer deaths in men
in the United States (1,
2). Although androgen ablation
therapy is effective in men with advanced disease for some time, the disease
subsequently progresses to the androgen-independent stage. The population of
prostate cells expressing neuroendocrine factors such as calcitonin (CT) also
increases during this progression
(3–5).
At this stage, the disease is metastatic and chemoresistant. Present evidence
suggests that cancer metastasis is usually preceded by the disruption of
normal cell-cell adhesion and the loss of integrity of the primary tumor site
(6,
7). This process may include
several genetic, molecular, and morphological changes characterized by
epithelial-to-mesenchymal transition (EMT)
(8–10).
The EMT is characterized by the loss of cell polarity, altered cell-cell and
cell-matrix adhesion, and acquisition of migratory, mesenchymal phenotype.
Other reported changes include down-regulation of E-cadherin, induction of
N-cadherin, release of β-catenin from junctional complexes, and its
translocation to the nucleus
(11–13).
However, the precise molecular mechanisms associated with this process are
obscure.Several growth factors, including hepatocyte growth factor, transforming
growth factor-β, vascular endothelial growth factor, and epidermal growth
factor, have been reported to induce EMT in tumor cell lines
(14–16).
We have shown that the expression of CT and its G protein-coupled receptor
(CTR) is remarkably higher in advanced PCs, and the CT-CTR autocrine axis is a
potent stimulator of PC cell tumorigenicity, invasion, and metastasis
(4,
17–19).
Although CT-stimulated increase in the motility and invasion of PC cells may
be mediated by CT-stimulated secretion of matrix metalloproteinases and
urokinase-type plasminogen activator, the precise molecular mechanisms
preceding these CTR actions remain to be elucidated
(18,
20). We tested the hypothesis
that CT induces biochemical and morphological changes associated with EMT to
increase the invasiveness of PC cells.Our results indicate that activation of the CT-CTR autocrine axis in
prostate cancer cells induced several changes associated with EMT such as
remodeling of tight and adherens junctions, cadherin switching, and activation
of WNT/β-catenin signaling. In contrast, the silencing of the CT-CTR axis
reversed this process. Moreover, cyclic AMP-dependent protein kinase (PKA)
plays a key role in this CT-CTR-mediated process. This is the first study
demonstrating the action of prostate CTR on junctional complexes and
WNT/β-catenin signaling of PC cell lines. 相似文献
20.
Furocoumarins from grapefruit juice and their effect on human CYP 3A4 and CYP 1B1 isoenzymes 总被引:2,自引:0,他引:2
Girennavar B Poulose SM Jayaprakasha GK Bhat NG Patil BS 《Bioorganic & medicinal chemistry》2006,14(8):2606-2612
Bioactive compounds present in grapefruit juice are known to increase the bioavailability of certain medications by acting as potent CYP 3A4 inhibitors. An efficient technique has been developed for isolation and purification of three furocoumarins. The isolated compounds have been tested for the inhibition of human CYP 1B1 isoform using specific substrates. Grapefruit juice was extracted with ethyl acetate (EtOAc) and the dried extract was loaded onto silica gel column chromatography. Further, column fractions were subjected to preparative HPLC to obtain three compounds. The purity of these compounds was analyzed by HPLC and structures were determined by NMR studies. The identified compounds, bergamottin, 6',7'-dihydroxybergamottin (DHB), and paradisin-A, were tested for their inhibitory effects on hydroxylase and O-dealkylase activities of human cytochrome P450 isoenzymes CYP 3A4 and CYP 1B1. Paradisin-A was found to be a potent CYP 3A4 inhibitor with an IC50 of 1.2 microM followed by DHB and bergamottin. All three compounds showed a substantial inhibitory effect on CYP 3A4 below 10 microM. Inhibitory effects on CYP 1B1 exhibited a greater variation due to the specificity of substrates. Paradisin A showed an IC50 of 3.56+/-0.12 microM for the ethoxy resorufin O-dealkylase (EROD) activity and 33.56+/-0.72 microM for the benzyloxy resorufin (BROD). DHB and bergamottin showed considerable variations for EROD and BROD activities with an IC50 of 7.17 microM and 13.86 microM, respectively. 相似文献